Parataxis Korea, Inc. (KOSDAQ:288330)
South Korea
· Delayed Price · Currency is KRW 416.00
-13.00 (-3.03%)
At close: Apr 7, 2026
Parataxis Korea Revenue
In the year 2025, Parataxis Korea had annual revenue of 9.00M KRW with 313.21% growth.
Revenue
9.00M
Revenue Growth
+313.21%
P/S Ratio
4,903.11
Revenue / Employee
428.57K
Employees
21
Market Cap
44.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | 6.82M | 313.21% |
| Dec 31, 2024 | 2.18M | -97.82M | -97.82% |
| Dec 31, 2023 | 100.00M | -2.92B | -96.69% |
| Dec 31, 2022 | 3.02B | 1.10B | 57.15% |
| Dec 31, 2021 | 1.92B | -4.42B | -69.65% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Poongjeon Pharmacy CO.,LTD. | 1.54B |
| J2KBIO | 32.97B |
| ADBiotech | 12.90B |
| MOA Life Plus | 11.22B |
| Kainos Medicine | 1.17B |
| Eutilex.Co.,Ltd | 10.29B |
| Epibiotech | 449.62M |
| NGeneBio | 21.24B |